Analysis of the cross-protective response induced by African swine fever virus recombinant vaccine ASFV-G-ΔI177L
The goal of the project is to analyse patterns of cross-protection induced by the African swine fever vaccine ASFV-G-ΔI177L against field isolates that are causing the disease in Africa.
Overview
Recombinant ASFV-G-ΔI177L is a rationally developed African swine fever virus live attenuated vaccine approved for commercial production by the Government of Vietnam.
The ASFV-G-ΔI177L vaccine was developed by genetic manipulation of the highly virulent African swine fever virus Georgia 2010 (ASFV-G) isolate genotype II.
The vaccine has been shown to be safe and efficacious in inducing solid protection against the virulent parental virus ASFV-G as well as another derivative virus isolated in Vietnam in 2019.
Lack of cross-protection among different strains of the African swine fever virus is generally accepted but has never been systematically analysed.
Therefore, this project aims to identify the patterns of cross-protection and immune mechanism elicited by the ASFV-G-ΔI177L vaccine.
Expected outcomes
- Increased understanding of the protective mechanism induced by other live attenuated African swine fever vaccines.
- Results on cross-protection induced by the African swine fever vaccine ASFV-G-ΔI177L against field isolates in Africa belonging to different genotypes.
